Abstract

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses trastuzumab deruxtecan (Enhertu),100 mg, powder for solution for IV infusion.
 Indication: For the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH−) breast cancer who have received at least 1 prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; patients with HR-positive breast cancer should have received at least 1 line of endocrine therapy and be no longer considered for endocrine therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
